Advertisement

NLS MSD

COVID-19 - November 22, 2021

EMA issues advice on use of molnupiravir for COVID-19 treatment

EMA’s human medicines committee (CHMP) has issued advice on the use of Merck’s (known as MSD outside the United States and Canada) Lagevrio (also known as molnupiravir or MK 4482) for the treatment of COVID-19. The medicine, which is currently not authorized in the EU, can be used to treat adults with COVID-19 who do […]

COVID-19 - November 5, 2021

Merck’s COVID-19 pill approved in the UK

Merck and Ridgeback’s Molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world. U.K.’s Medicines and Healthcare Products Regulatory Agency authorizes Molnupiravir for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. In the U.K., LAGEVRIO (lah-GEV-ree-oh) is […]

Clinical Trials - August 11, 2021

BioInvent enters clinical trial collaboration

BioInvent International has entered into a second clinical trial collaboration and supply agreement with MSD. The two companies will evaluate the combination of one of BioInvent’s anti-TNFR2 antibodies, BI-1808, and MSD’s anti-PD-1 therapy, KEYTRUDA in a Phase 1/2a clinical trial for patients with lung cancer and ovarian cancer. “We are very pleased we have reached […]

Working as a - December 14, 2020

A passion for the scientific side of medicine

For some people, testing the same thing over and over – tweaking, refining and then trying again – would seem tedious. For Charlotte Aagaard, however, trial-and-error to obtain final results are what fuels her passion for her career. “When at a certain time I was open for different opportunities, I worked with human papillomavirus (HPV) […]

Agreement - January 16, 2020

Microsoft and MSD in strategic partnership for Nordic and Baltic life science

The two companies have agreed on a partnership for the Nordic and Baltic markets with the aim to support healthcare. One possible field of cooperation is the use of cutting-edge technique, such as artificial intelligence, to support early diagnosis for i.a. lung cancer, they state. “The Nordic and Baltic states are at the forefront of […]

Clinical Trials - August 8, 2019

AstraZeneca’s PAOLA-1 trial met primary endpoint

AstraZeneca and MSD have announced positive results from the Phase III PAOLA-1 trial in women with advanced ovarian cancer. The trial, in the 1st-line maintenance setting, compared Lynparza(olaparib) added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in women with or without BRCA gene mutations. The second positive Phase III trial with Lynparza The trial met […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.